

**Supplementary Table 1. Patient characteristics related to transplantation**

Characteristic	Total (n = 43)	Ph-negative (n = 20)	Ph-positive (n = 23)	<i>p</i> value
Age, yr	38 (18–60)	32.5 (18–55)	49 (18–60)	0.002
> 35 years	27 (62.8)	8 (40.0)	19 (82.6)	
Sex				0.904
Male	23 (53.5)	10 (50.0)	13 (56.5)	
Female	20 (46.5)	10 (50.0)	10 (43.5)	
CD20 expression	51.8 (20.9–99.4)	56.1 (20.9–95.1)	48.5 (21–99.4)	0.988
Donor				0.759
Matched sibling	10 (23.3)	5 (25.0)	5 (21.7)	
Haploidentical	7 (16.3)	4 (20.0)	3 (13.0)	
Matched unrelated	26 (60.5)	11 (55.5)	15 (65.2)	
Conditioning				0.711
Myeloablative	17 (39.5)	9 (45.0)	8 (34.8)	
Non-myeloablative	26 (60.5)	11 (55.0)	15 (65.2)	
TBI	7 (16.3)	5 (25.0)	2 (8.7)	0.303
No. of total rituximab	6 (2–8)	6 (2–8)	6 (2–8)	0.955
No. of rituximab prior to allo-HCT	3 (2–8)	4 (2–8)	3 (2–8)	0.542
No. of rituximab after allo-HCT	1 (0–3)	1 (0–3)	2 (0–3)	0.442

Values are presented as median (range) or number (%).

Ph, Philadelphia; TBI, total body irradiation; allo-HCT, allogeneic hematopoietic cell transplantation.